These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35013795)

  • 1. Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes.
    Jiang L; Ye L; Ma L; Ren Y; Zhou X; Mei C; Xu G; Yang H; Lu C; Luo Y; Zhu S; Wang L; Shen C; Yang W; Zhang Q; Wang Y; Lang W; Han Y; Jin J; Tong H
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):845-856. PubMed ID: 35013795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes.
    Jiang L; Wang L; Shen C; Zhu S; Lang W; Luo Y; Zhang H; Yang W; Han Y; Ma L; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
    Am J Cancer Res; 2020; 10(12):4476-4487. PubMed ID: 33415012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
    Deng J; Wu X; Ling Y; Liu X; Zheng X; Ye W; Gong Y
    Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
    Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
    Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
    Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
    Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes.
    Belickova M; Vesela J; Jonasova A; Pejsova B; Votavova H; Merkerova MD; Zemanova Z; Brezinova J; Mikulenkova D; Lauermannova M; Valka J; Michalova K; Neuwirtova R; Cermak J
    Oncotarget; 2016 Jun; 7(24):36266-36279. PubMed ID: 27167113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
    Montalban-Bravo G; Kanagal-Shamanna R; Benton CB; Class CA; Chien KS; Sasaki K; Naqvi K; Alvarado Y; Kadia TM; Ravandi F; Daver N; Takahashi K; Jabbour E; Borthakur G; Pemmaraju N; Konopleva M; Soltysiak KA; Pierce SR; Bueso-Ramos CE; Patel KP; Kantarjian H; Garcia-Manero G
    Blood Adv; 2020 Feb; 4(3):482-495. PubMed ID: 32027746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
    Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
    Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.
    Wang W; Routbort MJ; Tang Z; Ok CY; Patel KP; Daver N; Garcia-Manero G; Medeiros LJ; Wang SA
    Eur J Haematol; 2017 Dec; 99(6):536-543. PubMed ID: 28926144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of mutation allele frequency on the risk stratification of myelodysplastic syndrome patients.
    Lee WH; Lin CC; Tsai CH; Tseng MH; Kuo YY; Liu MC; Tang JL; Sun HI; Chuang YK; Chou WC; Hou HA; Tien HF
    Am J Hematol; 2022 Dec; 97(12):1589-1598. PubMed ID: 36109871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
    Shah MV; Tran ENH; Shah S; Chhetri R; Baranwal A; Ladon D; Shultz C; Al-Kali A; Brown AL; Chen D; Scott HS; Greipp P; Thomas D; Alkhateeb HB; Singhal D; Gangat N; Kumar S; Patnaik MM; Hahn CN; Kok CH; Tefferi A; Hiwase DK
    Blood Cancer J; 2023 Apr; 13(1):51. PubMed ID: 37041128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
    Tefferi A; Fleti F; Chan O; Al Ali NH; Al-Kali A; Begna KH; Foran JM; Badar T; Khera N; Shah M; Hiwase D; Padron E; Sallman DA; Pardanani A; Arber DA; Orazi A; Reichard KK; He R; Ketterling RP; Gangat N; Komrokji R
    Br J Haematol; 2024 Apr; 204(4):1243-1248. PubMed ID: 38083865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of clinical and molecular features of MDS patients with complex karyotype in China.
    Ren Y; Mei C; Ye L; Luo Y; Zhou X; Yang H; Lin P; Xu W; Ma L; Jin J; Tong H
    Blood Cells Mol Dis; 2019 Mar; 75():13-19. PubMed ID: 30530101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
    Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
    Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion.
    Montoro MJ; Palomo L; Haferlach C; Acha P; Chan O; Navarro V; Kubota Y; Schulz FI; Meggendorfer M; Briski R; Al Ali N; Xicoy B; López-Cadenas F; Bosch F; González T; Eder LN; Jerez A; Wang YH; Campagna A; Santini V; Bernal Del Castillo T; Such E; Tien HF; Diaz Varela N; Platzbecker U; Haase D; Díez-Campelo M; Della Porta M; Garcia-Manero G; Wiseman DH; Germing U; Maciejewski JP; Komrokji RS; Sole F; Haferlach T; Valcárcel D
    Blood; 2024 Oct; 144(16):1722-1731. PubMed ID: 39074355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.
    Zhao D; Eladl E; Zarif M; Capo-Chichi JM; Schuh A; Atenafu E; Minden M; Chang H
    Cancer Med; 2023 Mar; 12(6):6511-6522. PubMed ID: 36394085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].
    Cai YN; Xu ZF; Li B; Qin TJ; Pan LJ; Qu SQ; Hu NB; Liu D; Huang HJ; Shi ZX; Zhang YD; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):379-386. PubMed ID: 32536134
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts.
    Shen K; Hu DY; Zhang ZB; Guo YS; Zhang FH; Chen SN
    Int J Lab Hematol; 2023 Jun; 45(3):344-352. PubMed ID: 36860196
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Bomben R; Rossi FM; Vit F; Bittolo T; D'Agaro T; Zucchetto A; Tissino E; Pozzo F; Vendramini E; Degan M; Zaina E; Cattarossi I; Varaschin P; Nanni P; Berton M; Braida A; Polesel J; Cohen JA; Santinelli E; Biagi A; Gentile M; Morabito F; Fronza G; Pozzato G; D'Arena G; Olivieri J; Bulian P; Pepper C; Hockaday A; Schuh A; Hillmen P; Rossi D; Chiarenza A; Zaja F; Di Raimondo F; Del Poeta G; Gattei V
    Clin Cancer Res; 2021 Oct; 27(20):5566-5575. PubMed ID: 34285062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.
    Dutta S; Moritz J; Pregartner G; Thallinger GG; Brandstätter I; Lind K; Rezania S; Lyssy F; Reinisch A; Zebisch A; Berghold A; Wölfler A; Sill H
    Ann Hematol; 2022 Apr; 101(4):837-846. PubMed ID: 35083527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.